CVRX News and Press, CVRx Inc. From 08/05/22

CVRx went public in June 2021, raising approximately $126 million in an IPO. The company is commercializing its neuromodulation cardiovascular medical device and related products. CVRx is growing revenue from a tiny base but is generating high operating losses and faces a variety ...

CVRx, Inc. (CVRX) Q2 2022 Earnings Conference Call July 28, 2022 05:30 p.m. ET Company Representatives Nadim Yared - President, Chief Executive Officer Jared Oasheim - Chief Financial Officer Mike Vallie - Westwicke, ICR Company Conference Call Participants...

Gainers: Ayala Pharmaceuticals ( AYLA ) +27% . GeoVax Labs ( GOVX ) +20% . Senti Biosciences ( SNTI ) +17% . Omeros ( OMER ) +15% . CVRx ( CVRX ) +9% . Losers: Nutriband ( NTRB ) -15% . Bausch Health Companies ...

MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the manag...

CVRx press release ( NASDAQ: CVRX ): Q2 GAAP EPS of -$0.54 misses by $0.01 . Revenue of $5.03M (+61.2% Y/Y) beats by $0.33M . For the third quarter of 2022, the Company expects to report total revenue between $5.5 million and $6.0 million. 2022 Outlook: ...

MINNEAPOLIS, July 28, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial ...

Shares of micro-cap company CVRx ( NASDAQ: CVRX ) rose as much as 11.7% to $7.57 in Monday trading, after Craig-Hallum research initiated the medical device firm with a buy rating. Craig-Hallum analyst Alexander Nowak gave CVRX stock a price target of $15, which is ...

MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans ...

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which was approved by the U.S...

CVRx's Barostim is a long-term compounder that presents with interesting economics. Clinical data is robust for the device and it continues to benefit from regulatory tailwinds. News around the device has been well priced into the stock, however, as investors price in growing syst...